Back to discover

Protein / target

Sodium/potassium-transporting ATPase subunit gamma

Encoded byFXYD2P54710Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Protein-macromolecule adaptor

Strongest disease association

Diabetes Mellitus, Type 2

Via encoding gene FXYD2 · Genetic evidence · score 0.74

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase

Subcellular location

Membrane
Domains and Gene Ontology detail (15)

Gene Ontology

  • Cbasolateral plasma membrane
  • Cextracellular exosome
  • Cplasma membrane
  • Csodium:potassium-exchanging ATPase complex
  • FATPase activator activity
  • Fprotein-macromolecule adaptor activity
  • Fsodium channel regulator activity
  • Pcellular hyperosmotic salinity response
  • Pestablishment or maintenance of transmembrane electrochemical gradient
  • Pnegative regulation of cell population proliferation
  • Ppositive regulation of sodium ion export across plasma membrane
  • Ppotassium ion import across plasma membrane

66 aa · 7 kDa · 2 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation
View underlying pathways (3)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

ATP1B1ATP1A4ATP1A3ATP1A1ATP1A2ATP1B2ATP1B3ATP1B4CLDN16FXYD1FXYD2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Atrial Fibrillation1 medicine
Heart Failure1 medicine
Broader indication categories (1)
Cardiovascular Diseases1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

5 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Digoxin
ApprovedInhibitor

Sodium/potassium-transporting ATPase inhibitor

Indicated for Atrial Fibrillation, Heart Failure, Cardiovascular Diseases

Acts on a complex — shared with ATP1A1, ATP1B2, ATP1B1 +4 more · 1 of 8 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene FXYD2

Gene-level evidence surfaced through the gene FXYD2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Diabetes Mellitus, Type 2
0.77Well supported

Genetic evidence dominant · Open Targets 0.47

Heart Failure
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

Atrial Fibrillation
0.73Moderately supported

Clinical evidence dominant · Open Targets 0.60

Renal hypomagnesemia 2
0.65Moderately supported

Genetic evidence dominant · Open Targets 0.55

Autosomal dominant primary hypomagnesemia with hypocalciuria
0.61Moderately supported

Genetic evidence dominant · Open Targets 0.52

View evidence synthesis (5)
Diabetes Mellitus, Type 2Well supported
0.77
agreement 0.670.88
Genetic84%Clinical10%Literature5%

Open Targets aggregate 0.47 · 3 independent evidence families

Heart FailureModerately supported
0.74
agreement 0.590.90
Clinical99%Literature1%

Open Targets aggregate 0.60 · 2 independent evidence families

Atrial FibrillationModerately supported
0.73
agreement 0.580.89
Clinical100%Literature0%

Open Targets aggregate 0.60 · 2 independent evidence families

Renal hypomagnesemia 2Moderately supported
0.65
agreement 0.510.79
Genetic100%Literature0%Genetic literaturedup

Open Targets aggregate 0.55 · 2 independent evidence families · 1 not counted as duplicate

Autosomal dominant primary hypomagnesemia with hypocalciuriaModerately supported
0.61
agreement 0.470.75
Genetic100%Literature0%Genetic literaturedup

Open Targets aggregate 0.52 · 2 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Heart Failure0.60
Atrial Fibrillation0.60
Renal hypomagnesemia 20.55
Autosomal dominant primary hypomagnesemia with hypocalciuria0.52
Diabetes Mellitus, Type 20.47
Neurodegenerative Diseases0.41

Drug development

6 compounds recorded · 5 approved · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 1 drug that targets this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (6)
ISTAROXIMEPhase 2 3
DIGOXINApproval
ACETYLDIGITOXINApproval
DESLANOSIDEApproval
DIGITOXINApproval
LANATOSIDE CApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Advanced Clinical and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (go cc high conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Advanced ClinicalSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via Digoxin · NCT06588699

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Label change2026-08-10

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  2. Trial status changed2026-07-22

    A Phase 1, 3-part, Open-label Study to Evaluate the Effects of KarXT Administration on the Pharmacokinetics of Midazolam, Fexofenadine, and Digoxin in Healthy Adult Participants

    Status changed to Completed · ClinicalTrials.gov · via Digoxin

  3. Trial status changed2026-07-20

    A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

    Status changed to Active, not recruiting · ClinicalTrials.gov · via Digoxin

  4. New publication2024-01-25
    Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.

    Drug safety · 2024 · 37 citations · Europe PMC · via Digoxin

  5. Label change2020-07-16

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  6. Label change2020-07-16

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  7. Label change2016-11-02

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  8. Label change2016-11-02

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  9. Label change2012-04-27

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  10. Label change2010-05-18

    Label change: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  11. Regulatory approval2003-08-21

    Approval: DIGOXIN (ANDA040481)

    fda · regulatory · fda · via Digoxin

  12. New publication2002-12-01
    Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

    JAMA · 2002 · 1,354 citations · Europe PMC · via Digoxin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.